Plain-English translation of NCT07118930 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing sivelestat sodium, a medication designed to protect your heart after you undergo off-pump coronary artery bypass surgery (a procedure that creates new pathways for blood to flow around blocked arteries). Half of the participants will receive the medication for 72 hours after surgery, and half will receive a placebo (salt water) to compare how well this treatment reduces heart injury.
Heart bypass surgery can sometimes cause inflammation and damage to heart muscle tissue. Researchers want to see if this medication can reduce that damage and help patients recover better after surgery.
You likely qualify if…
You likely don't qualify if…
You will undergo your scheduled off-pump coronary bypass surgery as planned. After surgery, you will be randomly assigned to receive either the protective medication or a placebo (salt water), which will be given continuously for 72 hours. During your hospital stay and recovery, doctors will monitor your heart function using blood tests and heart imaging to measure how well your heart is healing. You will have follow-up visits to track your recovery and any complications.
AI-generated summary from trial data · Aug 3, 2026 · Not medical advice
China